Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded studies raise concerns.
Three new reviews from Cochrane have found that GLP-1 medications can lead to significant weight loss, though questions remain about the influence of industry-funded research. Commissioned by the World Health Organization (WHO), these reviews will help shape forthcoming global guidelines on using these drugs to treat obesity.
The analyses focused on three medications known as GLP-1 receptor agonists and concluded that each produced clinically meaningful weight loss when compared with a placebo. However, researchers noted that data on long-term effects, side effects, and possible conflicts of interest are still uncertain or incomplete.
Glucagon-like peptide-1 (GLP-1) receptor agonists were first developed in the mid-2000s to help manage type 2 diabetes. In patients with this condition, particularly those with heart or kidney disease, the drugs improved blood sugar control, lowered the risk of related complications, aided in weight reduction, and decreased the likelihood of premature death.
In recent years, these drugs have also been tested in people with obesity. By mimicking a natural hormone that slows digestion and promotes a sense of fullness, they can help reduce food intake. In the United Kingdom, GLP-1 receptor agonists are now approved for weight management in individuals with obesity, or in those who are overweight with health conditions linked to excess weight, when combined with a calorie-controlled diet and physical activity.
GLP-1 Drugs: Generic [and Brand Names]:
- Semaglutide [Ozempic, Wegovy, Rybelsus]
- Liraglutide [Victoza, Saxenda]
- Dulaglutide [Trulicity]
- Exenatide [Byetta, Bydureon]
- Tirzepatide (GLP-1/GIP dual agonist) [Mounjaro, Zepbound]
GLP-1 drugs show promise for weight management
Across the reviews, tirzepatide, semaglutide, and liraglutide each led to significant weight loss compared to placebo after one to two years, with these effects likely to be sustained while treatment continues.
- Tirzepatide (administered once weekly) resulted in approximately a 16% weight reduction after 12 to 18 months. Evidence from 8 randomized controlled trials (6,361 participants) also suggested these effects could be maintained for up to 3.5 years, although long-term safety data were limited.
- Semaglutide (also injected weekly) reduced body weight by around 11% after 24 to 68 weeks, with effects likely sustained up to two years, drawing on 18 randomized controlled trials (27,949 participants). The drug increased the likelihood of achieving at least 5% body weight loss but was associated with higher rates of mild-to-moderate gastrointestinal side effects.
- Liraglutide (a daily injection) resulted in a more modest average weight reduction of around 4–5%, based on 24 trials (9,937 participants), but still increased the proportion of people achieving meaningful weight loss compared with placebo. Evidence for longer-term effects beyond two years was more limited.
Across the reviews, there was little to no difference between these drugs and placebo for major cardiovascular events, quality of life, or mortality. However, adverse events, particularly nausea and digestive symptoms, were more common among participants taking GLP-1 drugs, and some stopped treatment due to side effects.
“These drugs have the potential to bring about substantial weight loss, particularly in the first year,” says Juan Franco, co-lead researcher from Heinrich Heine University Düsseldorf, Germany. “It’s an exciting moment after decades of unsuccessful attempts to find effective treatments for people living with obesity.”
Independent research and equitable access are key
Most included studies were funded by the drug manufacturers, who were substantially involved in the planning, conduct, analysis, and reporting of the results. This raises concerns about potential conflicts of interest and the need for independent research.
The authors also emphasized that the wider use of these drugs should consider social and commercial determinants of health, including access, affordability, and insurance coverage, to avoid deepening existing health inequities among people living with obesity. The high prices of semaglutide and tirzepatide currently limit access, while liraglutide’s expired patent has allowed for more affordable generic versions to become available. Semaglutide’s patent will also expire in 2026.
Studies included in all three reviews were conducted mainly in middle- and high-income countries, with limited or no representation from regions such as Africa, Central America, and Southeast Asia. Considering the diversity in body composition, diet, and health behaviors across populations, the authors note the importance of assessing how these drugs perform in different global contexts.
“We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals,” says Eva Madrid, co-lead researcher from the Universidad de Valparaíso, Chile. “Weight regain after stopping treatment may affect the long-term sustainability of the observed benefits. More independent studies from a public health perspective are needed.”
The reviews stress that independent, long-term investigations are essential to inform clinical and public policy decisions and to better establish the role of GLP-1 receptor agonists in long-term weight management.
Commissioned by the World Health Organization, these reviews will inform forthcoming WHO guidelines on the use of GLP-1 receptor agonists for treating obesity. The guidelines are expected to launch soon, following a public consultation held in September.
References:
“Liraglutide for adults living with obesity” by Nicolás Meza, Javier Bracchiglione, Camila Micaela Escobar Liquitay, Eva Madrid, Lucia B Varela, Yang Guo, Gerard Urrútia, Selcuk Er, Sandra Tiller, Kamyar Shokraee, Felipe Alvarez Busco, Ivan Solà, Miranda Ocara Vargas, Victoria Novik A, Daniel Poloni and Juan VA Franco, 30 October 2025, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD016017
“Semaglutide for adults living with obesity” by Javier Bracchiglione, Nicolás Meza, Juan VA Franco, Camila Micaela Escobar Liquitay, Victoria Novik A, Miranda Ocara Vargas, Gabriel Lazcano, Daniel Poloni, Francisca Rinaldi Langlotz, Marta Roqué-Figuls, Sergio R Munoz and Eva Madrid, 30 October 2025, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD015092.pub2
“Tirzepatide for adults living with obesity” by Juan VA Franco, Yang Guo, Lucia B Varela, Zakariya Aqra, Murad Alhalahla, Mauricio Medina Rodriguez, Edison Leonardo Salvador Oscco, Bernarda Patiño Araujo, Susan Banda, Camila Micaela Escobar Liquitay, Javier Bracchiglione, Nicolás Meza and Eva Madrid, 30 October 2025, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD016018
News
New Molecule Blocks Deadliest Brain Cancer at Its Genetic Root
Researchers have identified a molecule that disrupts a critical gene in glioblastoma. Scientists at the UVA Comprehensive Cancer Center say they have found a small molecule that can shut down a gene tied to glioblastoma, a [...]
Scientists Finally Solve a 30-Year-Old Cancer Mystery Hidden in Rye Pollen
Nearly 30 years after rye pollen molecules were shown to slow tumor growth in animals, scientists have finally determined their exact three-dimensional structures. Nearly 30 years ago, researchers noticed something surprising in rye pollen: [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
How lipid nanoparticles carrying vaccines release their cargo
A study from FAU has shown that lipid nanoparticles restructure their membrane significantly after being absorbed into a cell and ending up in an acidic environment. Vaccines and other medicines are often packed in [...]
New book from NanoappsMedical Inc – Molecular Manufacturing: The Future of Nanomedicine
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
A Virus Designed in the Lab Could Help Defeat Antibiotic Resistance
Scientists can now design bacteria-killing viruses from DNA, opening a faster path to fighting superbugs. Bacteriophages have been used as treatments for bacterial infections for more than a century. Interest in these viruses is rising [...]
Sleep Deprivation Triggers a Strange Brain Cleanup
When you don’t sleep enough, your brain may clean itself at the exact moment you need it to think. Most people recognize the sensation. After a night of inadequate sleep, staying focused becomes harder [...]
Lab-grown corticospinal neurons offer new models for ALS and spinal injuries
Researchers have developed a way to grow a highly specialized subset of brain nerve cells that are involved in motor neuron disease and damaged in spinal injuries. Their study, published today in eLife as the final [...]
Urgent warning over deadly ‘brain swelling’ virus amid fears it could spread globally
Airports across Asia have been put on high alert after India confirmed two cases of the deadly Nipah virus in the state of West Bengal over the past month. Thailand, Nepal and Vietnam are among the [...]
This Vaccine Stops Bird Flu Before It Reaches the Lungs
A new nasal spray vaccine could stop bird flu at the door — blocking infection, reducing spread, and helping head off the next pandemic. Since first appearing in the United States in 2014, H5N1 [...]
These two viruses may become the next public health threats, scientists say
Two emerging pathogens with animal origins—influenza D virus and canine coronavirus—have so far been quietly flying under the radar, but researchers warn conditions are ripe for the viruses to spread more widely among humans. [...]
COVID-19 viral fragments shown to target and kill specific immune cells
COVID-19 viral fragments shown to target and kill specific immune cells in UCLA-led study Clues about extreme cases and omicron’s effects come from a cross-disciplinary international research team New research shows that after the [...]
Smaller Than a Grain of Salt: Engineers Create the World’s Tiniest Wireless Brain Implant
A salt-grain-sized neural implant can record and transmit brain activity wirelessly for extended periods. Researchers at Cornell University, working with collaborators, have created an extremely small neural implant that can sit on a grain of [...]
Scientists Develop a New Way To See Inside the Human Body Using 3D Color Imaging
A newly developed imaging method blends ultrasound and photoacoustics to capture both tissue structure and blood-vessel function in 3D. By blending two powerful imaging methods, researchers from Caltech and USC have developed a new way to [...]
Brain waves could help paralyzed patients move again
People with spinal cord injuries often lose the ability to move their arms or legs. In many cases, the nerves in the limbs remain healthy, and the brain continues to function normally. The loss of [...]
Scientists Discover a New “Cleanup Hub” Inside the Human Brain
A newly identified lymphatic drainage pathway along the middle meningeal artery reveals how the human brain clears waste. How does the brain clear away waste? This task is handled by the brain’s lymphatic drainage [...]
